Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer
06 January 2023 - 6:40AM
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused
on transforming the lives of people with fluid overload, today
announced the appointment of John Jefferies, MD, MPH, FACC, FHFSA
as Chief Medical Officer (CMO). In this new role, Dr. Jefferies
will provide Nuwellis with strategic guidance on clinical and
medical affairs issues, act as a liaison between the Company and
the medical community and serve as a key advisor on corporate
development matters.
“I am thrilled to welcome Dr. Jefferies in this new role of
CMO,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis.
“Dr. Jefferies’ pediatric training and expertise in cardiology and
heart failure make him the ideal person for this role as we prepare
to bring new products to market and continue expanding the body of
clinical evidence supporting ultrafiltration.”
Dr. Jefferies currently serves as the Jay M. Sullivan Endowed
Chair in Cardiovascular Medicine and Chief of Cardiology at the
University of Tennessee Health Science Center. He will continue in
this role while serving as CMO for Nuwellis. Dr. Jefferies began
his medical career with a combined residency in internal medicine
and pediatrics at the University of Kentucky. Dr. Jefferies then
completed a fellowship in general internal medicine and earned a
master’s degree in public health from the University of Kentucky
before completing an additional combined fellowship in adult
cardiovascular diseases and pediatric cardiology at the Baylor
College of Medicine. He has authored or co-authored more than 250
peer-reviewed manuscripts, functioned as lead editor for two
textbooks, and sits on the editorial boards of several journals.
Dr. Jefferies has served on the Nuwellis medical advisory board
since 2019.
“It’s an exciting time to be working with Nuwellis,” said Dr.
Jefferies. “I’ve seen firsthand how the company’s Aquadex therapy
can make a real difference for heart failure patients. I’m eager to
put my expertise to work to bring new technology to market and
expand the clinical data surrounding ultrafiltration, with the
ultimate goal of providing better outcomes for more patients in the
future.”
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is
a medical technology company dedicated to transforming the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
commercializing the Aquadex SmartFlow® system for ultrafiltration
therapy. Nuwellis is headquartered in Minneapolis, Minnesota, with
a wholly-owned subsidiary in Ireland.
About the Aquadex SmartFlow® System The Aquadex
SmartFlow system delivers clinically superior therapy using a
simple, flexible and smart method of removing excess fluid from
patients suffering from hypervolemia (fluid overload). The Aquadex
SmartFlow system is indicated for temporary (up to 8 hours) or
extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the new
market opportunities and anticipated growth in 2023 and beyond.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our ability to execute on our commercialization strategy, the
impact of the COVID-19 pandemic, the possibility that we may be
unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities,
benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability
to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak only as
of the date when made. Nuwellis does not assume any obligation to
publicly update or revise any forward-looking statements, whether
due to new information, future events or otherwise.
CONTACTS
INVESTORS: Vivian Cervantes Gilmartin Group
ir@nuwellis.com
MEDIA: Annika Parish Health+Commerce
annika@healthandcommerce.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2023 to Jul 2024